WO2014193973A3 - Antibody locker for the inactivation of protein drug - Google Patents

Antibody locker for the inactivation of protein drug Download PDF

Info

Publication number
WO2014193973A3
WO2014193973A3 PCT/US2014/039821 US2014039821W WO2014193973A3 WO 2014193973 A3 WO2014193973 A3 WO 2014193973A3 US 2014039821 W US2014039821 W US 2014039821W WO 2014193973 A3 WO2014193973 A3 WO 2014193973A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
hinge
locker
inactivation
cleavable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2014/039821
Other languages
French (fr)
Other versions
WO2014193973A2 (en
Inventor
Tian-Lu Cheng
Chih-Hung Chuang
Hsiu-Fen KO
Yun-Chi LU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kaohsiung Medical University
DCB USA LLC
Original Assignee
Kaohsiung Medical University
DCB USA LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN201480031238.9A priority Critical patent/CN105377297B/en
Priority to JP2016516786A priority patent/JP6545666B2/en
Priority to SG11201509595PA priority patent/SG11201509595PA/en
Priority to CA2913051A priority patent/CA2913051C/en
Priority to AU2014274215A priority patent/AU2014274215B2/en
Priority to EA201592049A priority patent/EA035322B1/en
Priority to EP14803825.0A priority patent/EP3003370B1/en
Priority to KR1020157036785A priority patent/KR102182485B1/en
Priority to HK16109736.2A priority patent/HK1221426B/en
Application filed by Kaohsiung Medical University, DCB USA LLC filed Critical Kaohsiung Medical University
Priority to MX2015016329A priority patent/MX2015016329A/en
Priority to US14/893,509 priority patent/US10633453B2/en
Publication of WO2014193973A2 publication Critical patent/WO2014193973A2/en
Publication of WO2014193973A3 publication Critical patent/WO2014193973A3/en
Priority to IL242772A priority patent/IL242772B/en
Priority to ZA2015/08673A priority patent/ZA201508673B/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Disclosed herein is a hinge antibody capable of being selectively activated in a target cell or tissue to treat a condition therein. The hinge antibody includes a functional antibody, two inhibitory domains and four cleavable linkers. The functional antibody is capable of treating the condition in an activated state, and has two light chains and two heavy chains. Each inhibitory domain includes a hinge domain of an immunoglobulin and consists of two peptide arms. Each cleavable linker includes a peptide substrate cleavable by an enzyme specifically or highly expressed in the target cell or tissue, and connects one of the peptide arms of the inhibitory domains to the N-terminal of one of the light chains and heavy chains of the functional antibody. Also disclosed herein are methods for preparing and using this hinge antibody.
PCT/US2014/039821 2013-05-28 2014-05-28 Antibody locker for the inactivation of protein drug Ceased WO2014193973A2 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
HK16109736.2A HK1221426B (en) 2013-05-28 2014-05-28 Antibody locker for the inactivation of protein drug
SG11201509595PA SG11201509595PA (en) 2013-05-28 2014-05-28 Antibody locker for the inactivation of protein drug
CA2913051A CA2913051C (en) 2013-05-28 2014-05-28 Antibody locker for the inactivation of protein drug
AU2014274215A AU2014274215B2 (en) 2013-05-28 2014-05-28 Antibody locker for the inactivation of protein drug
EA201592049A EA035322B1 (en) 2013-05-28 2014-05-28 Antibody locker for the inactivation of protein drug
EP14803825.0A EP3003370B1 (en) 2013-05-28 2014-05-28 Antibody locker for the inactivation of protein drug
KR1020157036785A KR102182485B1 (en) 2013-05-28 2014-05-28 Antibody locker for the inactivation of protein drug
CN201480031238.9A CN105377297B (en) 2013-05-28 2014-05-28 Antibody lock for pharmaceutical grade protein inactivation
MX2015016329A MX2015016329A (en) 2013-05-28 2014-05-28 Antibody locker for the inactivation of protein drug.
JP2016516786A JP6545666B2 (en) 2013-05-28 2014-05-28 Antibody locker for protein drug inactivation
US14/893,509 US10633453B2 (en) 2013-05-28 2014-05-28 Antibody locker for the inactivation of protein drug
IL242772A IL242772B (en) 2013-05-28 2015-11-25 Selectively activatable hinge antibodies, systems for producing same and uses thereof
ZA2015/08673A ZA201508673B (en) 2013-05-28 2015-11-25 Antibody locker for the inactivation of protein drug

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361827763P 2013-05-28 2013-05-28
US61/827,763 2013-05-28

Publications (2)

Publication Number Publication Date
WO2014193973A2 WO2014193973A2 (en) 2014-12-04
WO2014193973A3 true WO2014193973A3 (en) 2015-02-19

Family

ID=51989521

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/039821 Ceased WO2014193973A2 (en) 2013-05-28 2014-05-28 Antibody locker for the inactivation of protein drug

Country Status (14)

Country Link
US (1) US10633453B2 (en)
EP (1) EP3003370B1 (en)
JP (1) JP6545666B2 (en)
KR (1) KR102182485B1 (en)
CN (1) CN105377297B (en)
AU (1) AU2014274215B2 (en)
CA (1) CA2913051C (en)
EA (1) EA035322B1 (en)
IL (1) IL242772B (en)
MX (1) MX2015016329A (en)
SG (2) SG11201509595PA (en)
TW (1) TWI582111B (en)
WO (1) WO2014193973A2 (en)
ZA (1) ZA201508673B (en)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014193973A2 (en) 2013-05-28 2014-12-04 Dcb-Usa Llc Antibody locker for the inactivation of protein drug
CA2925106C (en) 2013-09-25 2023-11-14 Cytomx Therapeutics, Inc. Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof
UA129760C2 (en) 2013-12-17 2025-07-30 Дженентек, Інк. ANTI-CD3 ANTIBODY AND METHOD OF USE THEREOF
IL270562B (en) 2014-01-31 2022-08-01 Cytomx Therapeutics Inc Matriptase and u-plasminogen activator polypeptide substrates and other cleanable moieties, compositions comprising same and uses thereof
KR20170066421A (en) 2014-09-12 2017-06-14 제넨테크, 인크. Anti-cll-1 antibodies and immunoconjugates
MA41374A (en) 2015-01-20 2017-11-28 Cytomx Therapeutics Inc MATRIX METALLOPROTEASE CLIVABLE AND SERINE PROTEASE CLIVABLE SUBSTRATES AND METHODS OF USE THEREOF
EP4122492A1 (en) 2015-02-25 2023-01-25 Memorial Sloan Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
KR20180006916A (en) 2015-04-17 2018-01-19 메모리얼 슬로안-케터링 캔서 센터 Use of MVA or MVA delta E3L as an immunotherapeutic agent for solid tumors
EP3778640A1 (en) * 2015-05-01 2021-02-17 Genentech, Inc. Masked anti-cd3 antibodies and methods of use
EA201792573A1 (en) 2015-05-21 2018-04-30 Харпун Терапьютикс, Инк. TRISPECIFIC RELATED PROTEINS AND METHODS OF THEIR APPLICATION
EP3310378B1 (en) 2015-06-16 2024-01-24 F. Hoffmann-La Roche AG Anti-cll-1 antibodies and methods of use
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide assembly and methods of making and using the same
EP3397282A4 (en) * 2015-12-30 2019-08-07 Momenta Pharmaceuticals, Inc. METHODS ASSOCIATED WITH BIOLOGICAL PRODUCTS
CN109152827B (en) 2016-02-25 2023-07-21 纪念斯隆凯特琳癌症中心 Recombinant MVA or MVAΔE3L expressing human FLT3L and its use as an immunotherapeutic agent against solid tumors
JP7025339B2 (en) 2016-02-25 2022-02-24 メモリアル スローン ケタリング キャンサー センター Replicable attenuated vaccinia virus with or without expression of human FLT3L or GM-CSF with thymidine kinase deletion for cancer immunotherapy
WO2017165306A1 (en) * 2016-03-20 2017-09-28 Middle Tennessee State University ASSAY FOR HIGH-THROUGHPUT lDENTIFICATION OF THERAPEUTIC COMPOUNDS
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
CA3024448C (en) * 2016-05-18 2025-09-09 Voyager Therapeutics, Inc. Modulatory polynucleotides
JP7101621B2 (en) 2016-05-20 2022-07-15 ハープーン セラピューティクス，インク． Single domain serum albumin binding protein
CN107446016A (en) * 2016-05-30 2017-12-08 上海交通大学 A kind of cell-penetrating peptide of Stearate Modified and its preparation and application
WO2017211278A1 (en) * 2016-06-06 2017-12-14 Asclepiumm Taiwan Co., Ltd Antibody fusion proteins for drug delivery
MX2019004775A (en) * 2016-11-03 2019-08-05 Squibb Bristol Myers Co Activatable anti-ctla-4 antibodies and uses thereof.
WO2018093821A1 (en) 2016-11-15 2018-05-24 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
EA201991353A1 (en) 2016-12-09 2019-11-29 BIVALENT ANTIBODIES MASKED BY SPIRALIZED SPIRALS
WO2018126232A1 (en) * 2016-12-29 2018-07-05 Development Center For Biotechnology Klk6-mediated cns-specific antibody prodrug activation
EP3621646A4 (en) 2017-05-12 2021-06-02 Memorial Sloan Kettering Cancer Center USEFUL VACCINE VIRUS MUTANTS FOR ANTI-CANCER IMMUNOTHERAPY
EP3625253A4 (en) 2017-05-16 2021-03-24 Scalmibio, Inc. Activatable antibodies and methods of use thereof
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B cell maturation antigen binding proteins
HRP20241268T1 (en) 2017-10-13 2024-12-06 Harpoon Therapeutics, Inc. TRISPECIFIC PROTEINS AND APPLICATION PROCEDURES
KR20200091901A (en) 2017-12-01 2020-07-31 시애틀 지네틱스, 인크. CD47 antibody and its use for treating cancer
JP7475275B2 (en) 2018-02-08 2024-04-26 ジェネンテック， インコーポレイテッド Bispecific antigen-binding molecules and methods of use thereof
KR102245552B1 (en) * 2018-02-28 2021-04-29 부산대학교 산학협력단 Nanodrug Composites, preparation method therof, and use for the same
AU2019234642A1 (en) * 2018-03-13 2020-09-24 Memorial Sloan Kettering Cancer Center Oncolytic vaccinia virus expressing immune checkpoint blockade for cancer immunotherapy
AU2019336148B2 (en) 2018-09-06 2025-08-14 Momenta Pharmaceuticals, Inc. Methods of continuous cell culture
BR112021004692A2 (en) 2018-09-15 2021-06-08 Memorial Sloan Kettering Cancer Center Recombinant poxviruses for cancer immunotherapy
WO2020061482A1 (en) 2018-09-21 2020-03-26 Harpoon Therapeutics, Inc. Egfr binding proteins and methods of use
SG11202103022WA (en) 2018-09-25 2021-04-29 Harpoon Therapeutics Inc Dll3 binding proteins and methods of use
MY205459A (en) 2018-12-06 2024-10-22 Cytomx Therapeutics Inc Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof
WO2020142275A1 (en) 2018-12-31 2020-07-09 Momenta Pharmaceuticals, Inc. Methods of producing ustekinumab
US20220306727A1 (en) 2019-06-05 2022-09-29 Seagen Inc. Methods of Purifying Masked Antibodies
US20220233709A1 (en) 2019-06-05 2022-07-28 Seagen Inc. Masked Antibody Formulations
CA3196539A1 (en) 2020-11-04 2022-05-12 Chi-Chung Li Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
AU2021374594B2 (en) 2020-11-04 2026-03-05 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
KR20230100732A (en) 2020-11-04 2023-07-05 제넨테크, 인크. Subcutaneous Administration of Anti-CD20/Anti-CD3 Bispecific Antibodies
US12291575B2 (en) 2021-05-14 2025-05-06 Genentech, Inc. Methods for treatment of CD20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
TW202317623A (en) 2021-06-14 2023-05-01 美商再生元醫藥公司 Il2-based therapeutics and methods of use thereof
EP4370211A1 (en) 2021-07-14 2024-05-22 Seagen Inc. Antibody masking domains
WO2023049825A1 (en) 2021-09-24 2023-03-30 Seagen Inc. Improved antibody masking domains
WO2023064945A2 (en) * 2021-10-15 2023-04-20 Harpoon Therapeutics, Inc. Conditional activation of immunoglobulin molecules
CA3251998A1 (en) 2022-05-16 2023-11-23 Byondis B.V. NEW MASKED ANTIBODIES

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060018903A1 (en) * 2001-11-12 2006-01-26 Koen Hellendoorn TNF alpha-binding polypeptide compositions and methods
US20080292628A1 (en) * 2004-10-12 2008-11-27 Amprotein Corporation Chimeric Protein
US20100029497A1 (en) * 2006-07-05 2010-02-04 F-Star Biotechnologische Forschungs-Und Entwicklungsges.M.B.H. Method for engineering immunoglobulins
US20100248279A1 (en) * 2007-09-07 2010-09-30 Kyoto University Substrate probe, enzyme-activity detection method by a multi-dimensional nuclear magnetic resonance method and enzyme-activity imaging method
US20110287009A1 (en) * 2010-04-23 2011-11-24 Genentech, Inc. Production of Heteromultimeric Proteins
US20120244154A1 (en) * 2007-08-22 2012-09-27 Patrick Daugherty Activatable Binding Polypeptides and Methods of Identification and Use Thereof
US20130011394A1 (en) * 2011-06-22 2013-01-10 Hoffmann-La Roche Inc. Complexes comprising mhc class i fusion polypeptides and antigen-specific antibodies and methods of use

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
GB9322156D0 (en) 1993-10-27 1993-12-15 Univ Newcastel Upon Tyne Activation of molecules
AU5509296A (en) 1995-05-03 1996-11-21 Colin Henry Self Bispecific antibodies in which the binding capability is rev ersibly inhibited by a photocleavable moiety
US20040014652A1 (en) 2000-06-01 2004-01-22 Andre Trouet Tumor activated prodrug compounds and methods of making and using the same
US7238505B2 (en) 2000-10-04 2007-07-03 Ahram Biosystems Inc. Immobilized DNA polymerase
US20030219402A1 (en) 2002-02-14 2003-11-27 Rutter William J. Chimeric molecules for cleavage in a treated host
US20040109855A1 (en) 2002-07-23 2004-06-10 Herman Waldmann Therapeutic antibodies with reduced side effect
AU2004248155B2 (en) 2003-06-09 2008-10-23 Redox-Reactive Reagents L.L.C. Method of altering the binding specificity of plasma proteins by oxidation-reduction reactions
GB0404187D0 (en) 2004-02-25 2004-03-31 Biotransformations Ltd Binding agents
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
GB0605702D0 (en) 2006-03-21 2006-05-03 Biotransformations Ltd Materials and methods for immune cell stimulation
WO2009021754A2 (en) 2007-08-15 2009-02-19 Bayer Schering Pharma Aktiengesellschaft Monospecific and multispecific antibodies and method of use
GB0716160D0 (en) 2007-08-17 2007-09-26 Biotransformations Ltd Materials and methods for treating cancers which express folate receptors
EP2356131A4 (en) 2008-12-08 2012-09-12 Tegopharm Corp Masking ligands for reversible inhibition of multivalent compounds
US20100189651A1 (en) * 2009-01-12 2010-07-29 Cytomx Therapeutics, Llc Modified antibody compositions, methods of making and using thereof
JP5861223B2 (en) * 2009-02-23 2016-02-16 サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. Proprotein and its use
KR20120108967A (en) 2009-09-16 2012-10-05 제넨테크, 인크. Coiled coil and/or tether containing protein complexes and uses thereof
WO2012025530A1 (en) 2010-08-24 2012-03-01 F. Hoffmann-La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
MX340556B (en) 2010-08-24 2016-07-14 Roche Glycart Ag Activatable bispecific antibodies.
CN103501815B (en) 2010-10-08 2016-09-28 希望之城公司 Monoclonal antibody framework combination interface, interposition delivery system and using method thereof for interposition
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
CN104185474B (en) 2012-03-30 2017-08-25 拜尔健康护理有限责任公司 Protease Regulated Antibodies
CN104540518A (en) 2012-04-27 2015-04-22 西托姆克斯治疗公司 Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
MX2014016038A (en) 2012-06-22 2015-08-14 Cytomx Therapeutics Inc Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof.
WO2013192546A1 (en) 2012-06-22 2013-12-27 Cytomx Therapeutics, Inc. Activatable antibodies having non-binding steric moieties and mehtods of using the same
US9487590B2 (en) 2012-09-25 2016-11-08 Cytomx Therapeutics, Inc. Activatable antibodies that bind interleukin-6 receptor and methods of use thereof
CA2906095A1 (en) 2013-03-15 2014-09-18 Bayer Healthcare Llc Pro-drug antibodies against tissue factor pathway inhibitor
WO2014193973A2 (en) 2013-05-28 2014-12-04 Dcb-Usa Llc Antibody locker for the inactivation of protein drug
CN105722859B (en) 2013-07-25 2021-05-07 西托姆克斯治疗公司 Multispecific antibodies, multispecific activatable antibodies, and methods of use thereof
CA2925106C (en) 2013-09-25 2023-11-14 Cytomx Therapeutics, Inc. Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof
WO2015066279A2 (en) 2013-10-30 2015-05-07 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
DE102014201538A1 (en) 2014-01-29 2015-07-30 Robert Bosch Gmbh A method for driving a parking lot management system for at least one parking lot and parking lot management system for at least one parking lot

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060018903A1 (en) * 2001-11-12 2006-01-26 Koen Hellendoorn TNF alpha-binding polypeptide compositions and methods
US20080292628A1 (en) * 2004-10-12 2008-11-27 Amprotein Corporation Chimeric Protein
US20100029497A1 (en) * 2006-07-05 2010-02-04 F-Star Biotechnologische Forschungs-Und Entwicklungsges.M.B.H. Method for engineering immunoglobulins
US20120244154A1 (en) * 2007-08-22 2012-09-27 Patrick Daugherty Activatable Binding Polypeptides and Methods of Identification and Use Thereof
US20100248279A1 (en) * 2007-09-07 2010-09-30 Kyoto University Substrate probe, enzyme-activity detection method by a multi-dimensional nuclear magnetic resonance method and enzyme-activity imaging method
US20110287009A1 (en) * 2010-04-23 2011-11-24 Genentech, Inc. Production of Heteromultimeric Proteins
US20130011394A1 (en) * 2011-06-22 2013-01-10 Hoffmann-La Roche Inc. Complexes comprising mhc class i fusion polypeptides and antigen-specific antibodies and methods of use

Also Published As

Publication number Publication date
EP3003370B1 (en) 2020-01-22
KR20160032041A (en) 2016-03-23
EP3003370A2 (en) 2016-04-13
TWI582111B (en) 2017-05-11
KR102182485B1 (en) 2020-11-25
EA035322B1 (en) 2020-05-28
IL242772B (en) 2020-04-30
MX2015016329A (en) 2016-07-20
CN105377297B (en) 2019-09-17
ZA201508673B (en) 2017-05-31
JP6545666B2 (en) 2019-07-17
US20160185875A1 (en) 2016-06-30
SG11201509595PA (en) 2015-12-30
AU2014274215A1 (en) 2015-12-03
WO2014193973A2 (en) 2014-12-04
AU2014274215B2 (en) 2019-02-28
HK1221426A1 (en) 2017-06-02
TW201520230A (en) 2015-06-01
CA2913051A1 (en) 2014-12-04
EP3003370A4 (en) 2017-01-25
SG10201710727UA (en) 2018-02-27
CN105377297A (en) 2016-03-02
US10633453B2 (en) 2020-04-28
EA201592049A1 (en) 2016-04-29
JP2016520614A (en) 2016-07-14
CA2913051C (en) 2023-09-05

Similar Documents

Publication Publication Date Title
WO2014193973A3 (en) Antibody locker for the inactivation of protein drug
WO2018091740A3 (en) Novel anti_cd137 antibodies and uses thereof
EP4434587A3 (en) Antibody variable domain combinations targeting the nkg2d receptor
TN2013000390A1 (en) Bispecific binding molecules binding to vegf and ang2
NZ612394A (en) Tnf-α binding proteins
BR112019024654A2 (en) binding protein nkg2d, cd16 and ror1 or ror2
PH12014502179B1 (en) Ang2-binding molecules
EA201390666A1 (en) CXCR2-BONDING POLYPEPTIDES
BR112016011025A2 (en) antibody polypeptides and their uses
PH12013500410B1 (en) Vegf-binding molecules
BR112015013127A2 (en) immunotherapy with binding agents
BR112013004581A2 (en) dual variable domain immunoglobulins and their uses
WO2017151971A3 (en) METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
WO2016061286A3 (en) Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
WO2017015622A8 (en) Gdf11 binding proteins and uses thereof
EP4349868A3 (en) Humanized and chimeric monoclonal antibodies to cd47
EA200971077A1 (en) HETEROCYCLIC KINASE MODULATORS
WO2009070294A3 (en) Inhibition of macrophage-stimulating protein receptor (ron) and methods of treatment thereof
WO2009044173A3 (en) Methods of treating cancer using notch pathway inhibitors
AR102595A1 (en) ANTI-ANG2 ANTIBODIES AND METHODS OF USE
HK1250737A1 (en) Antibody molecules which bind cd79
PH12013502031A1 (en) BISPECIFIC BINDING MOLECULES BINDING TO D114 AND Ang2
WO2012014078A3 (en) Method of treatment of organic diseases of nervous system, psychoorganic syndrome and encephalopathy
WO2010072740A3 (en) TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREOF
WO2010011952A3 (en) Flip death effector domain derived peptides for inducing autophagy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14803825

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2913051

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 201592049

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 242772

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2016516786

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2015/016329

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2014274215

Country of ref document: AU

Date of ref document: 20140528

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2014803825

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20157036785

Country of ref document: KR

Kind code of ref document: A